Navigation Links
NeoStem's CEO Letter to Shareholders
Date:1/3/2012

, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic, poised to commence enrollment of patients in a Phase 2 trial for the preservation of heart function after a heart attack.  Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with our partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes is an endogenous pluripotent non-embryonic cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit www.neostem.com and thechairmansblog.com/robin-l-smith.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business and medical strategy, including with
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
2. CTI Receives NASDAQ Letter
3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
4. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
5. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
6. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
7. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
8. Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
10. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
11. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 BioHealth ... on commercializing market-relevant biohealth innovations and increasing access to ... announced today that venture capitalist, Tania Fernandez , ... advisor. Dr. Fernandez will be a member of the ... will provide up to $50 million in seed and ...
(Date:9/30/2014)... September 30, 2014 The custom stainless ... Boston Product Show 2014. The Boston Area Chapter of ... 23rd annual, day-long event for Wed., Oct. 1 at ... to be the largest in ISPE Boston’s long history, ... of 3,000 attendees expected. , HOLLOWAY AMERICA President ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Contract Research Organization Exceeds Expectations, MEMPHIS, ... Contract Research,Organization exclusively focused on oncology, announced ... exceeded projections as the company continues,to experience ... to,ACORN,s ability to consistently exceed client expectations, ...
... Pharma, Inc., a,diversified specialty pharmaceutical company, announced ... issues in the treatment of moderate to,severe ... dry eye medication Lacrisert(R),(hydroxypropyl cellulose ophthalmic insert), ... helps to retain,moisture, stabilize the tear film, ...
... -- 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company ... primarily in China,today announced that it has filed ... for approval of NuLeusin for the treatment of ... is expected to,be the only treatment of this ...
Cached Biology Technology:ACORN CRO Continues Growth in Strong Third Quarter 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 53SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... A cell,s genome maintains its integrity by organizing ... DNA called heterochromatin. In the comparatively simple organism fission ... plays an essential role in assembling heterochromatin, which keeps ... Central to this process is a large protein complex ...
... of vitamin C were associated with higher levels of high ... issues or death for heart failure patients, in research presented ... to those with high vitamin C intake from food, heart ... intake were 2.4 times more likely to have higher levels ...
... The hermaphroditic cleaner shrimp Lysmata amboinensis usually ... structure. New research published in BioMed Central,s open access journal ... any group larger than two, viciously attack and kill each ... amboinensis are protandric simultaneous hermaphrodites. This means that they ...
Cached Biology News:CSHL team solves a protein complex's molecular structure to explain its role in gene silencing 2Low vitamin C levels may raise heart failure patients' risk 2Violent passions -- jealous cleaner shrimp murder their rivals 2
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
ANTI S. ENT TOX BC2D...
... Anti-Major DNA-binding protein(DBP). Protein ... NP_001343 ELISA titre using ... Suggested conditions for Western Blot: ... buffer, and HRP conjugated anti-Rabbit IgG should ...
Biology Products: